Athira Pharma Inc. (LONA)
Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
7. 22
-0.59
-7.5544%
$
36.9M Market Cap
- P/E Ratio
- Div Yield
32,357 Volume
- Eps
$ 7.81
Previous Close Want to track LONA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
LONA closed today lower at $7.22, a decrease of -7.5544% from yesterday's close, completing a monthly decrease of -21.265% or -$1.95. Over the past 12 months, LONA stock lost -4.4974%.
LONA is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Athira Pharma Inc. has completed 1 stock splits, with the recent split occurring on Sep 18, 2025.
The company's stock is traded on one exchange.
LONA Chart
Athira Pharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 150 | $621 | $1,380 | $759 | 122.22% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 6 | $62 | $48.12 | -$13.88 | -22.39% |
 Jim Harding Propel Bio Management LLC | 149,279 | $618,015 | $1.22M | $597,862.45 | 96.74% |
 Jay Annis Annis Gardner Whiting Capital Advisors, LLC | 1,000 | $10,280 | $8,200 | -$2,080 | -20.23% |
 Ian Jameson American Capital Advisory, LLC | 200 | $828 | $1,628 | $800 | 96.62% |
Athira Pharma Inc. (LONA) FAQ
What is the stock price today?
The current price is $7.22.
On which exchange is it traded?
Athira Pharma Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is LONA.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 36.9M.
Has Athira Pharma Inc. ever had a stock split?
Athira Pharma Inc. had 1 splits and the recent split was on Sep 18, 2025.
Athira Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark J. Litton CEO | NASDAQ (CM) Exchange | 04746L203 CUSIP |
| US Country | 19 Employees | - Last Dividend | 18 Sep 2025 Last Split | - IPO Date |
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Contact Information
Address: 18706 North Creek Parkway
Phone: 425 620 8501
Website: https://leonabio.com
